2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
92
Breast Neoplasms
69
Prostatic Neoplasms
33
Triple Negative Breast Neoplasms
32
Neoplasms
26
Fallopian Tube Neoplasms
25
Neoplasm Metastasis
21
Endometrial Neoplasms
19
Pancreatic Neoplasms
18
Small Cell Lung Carcinoma
13
Carcinoma, Ovarian Epithelial
12
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
9
Sarcoma
9
Recurrence
9
Lung Neoplasms
9
Fanconi Anemia, Complementation Group D1
9
Squamous Cell Carcinoma of Head and Neck
8
Glioma
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Glioblastoma
7
Colorectal Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
5
Lymphoma, Non-Hodgkin
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Solid Tumors
4
Osteosarcoma
4
Interventions
Iodine-131
21
lenvatinib
17
Magnetic Resonance Spectroscopy
17
trametinib
13
Sorafenib
13
Thyrotropin Alfa
12
pembrolizumab
11
dabrafenib
11
Thyroidectomy
10
Surgical Procedures, Operative
10
Thyroxine
9
Paclitaxel
9
vandetanib
8
selpercatinib
8
Sunitinib
7
Nivolumab
7
Fluorodeoxyglucose F18
7
cabozantinib
6
anlotinib
6
Everolimus
6
Biopsy
6
pazopanib
5
Vemurafenib
5
Triiodothyronine
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Iodine-124
5
Cyclophosphamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled